BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
8/27/2018 7:22:43 AM | Browse: 1060 | Download: 903
 |
Received |
|
2018-03-29 04:29 |
|
Peer-Review Started |
|
2018-03-29 09:25 |
|
To Make the First Decision |
|
2018-04-27 02:06 |
|
Return for Revision |
|
2018-04-27 06:04 |
|
Revised |
|
2018-05-09 13:03 |
|
Second Decision |
|
2018-06-25 08:51 |
 |
Accepted by Journal Editor-in-Chief |
|
|
|
Accepted by Executive Editor-in-Chief |
|
2018-06-25 19:19 |
|
Articles in Press |
|
2018-06-25 19:19 |
|
Publication Fee Transferred |
|
|
|
Edit the Manuscript by Language Editor |
|
|
|
Typeset the Manuscript |
|
2018-08-27 01:38 |
|
Publish the Manuscript Online |
|
2018-08-27 07:22 |
| ISSN |
1007-9327 (print) and 2219-2840 (online) |
| Open Access |
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ |
| Copyright |
© The Author(s) 2018. Published by Baishideng Publishing Group Inc. All rights reserved. |
| Article Reprints |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
|
| Permissions |
For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
|
| Publisher |
Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA |
| Website |
http://www.wjgnet.com |
| Category |
Gastroenterology & Hepatology |
| Manuscript Type |
Review |
| Article Title |
Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases
|
| Manuscript Source |
Invited Manuscript |
| All Author List |
Jason Reinglas, Lorant Gonczi, Zsuzsanna Kurti, Talat Bessissow and Peter L Lakatos |
| ORCID |
|
| Funding Agency and Grant Number |
|
| Corresponding Author |
Peter L Lakatos, DSc, MD, PhD, Professor, Division of Gastroenterology, Montreal General Hospital C7-200, McGill University Health Center, 1650 Cedar Avenue, Quebec H3G1A4, Canada. kislakpet99@gmail.com |
| Key Words |
Inflammatory bowel disease; Small molecule; Positioning; Biologic; Therapeutic |
| Core Tip |
Anti-tumor necrosis factor therapy should be considered as first-line therapy in patients with complicated Crohn’s disease and in acute-severe ulcerative colitis. Beyond these specific circumstances, the positioning of novel biologics and small molecules depends on the patient’s medical history, preference and disease phenotype. The efficacy and safety of using immunomodulatory therapy can be enhanced by adhering to therapeutic algorithms and using a ‘treat-to-target’ approach. The risks for adverse events due to poor disease control outweigh the risks associated with early aggressive therapy. In the setting of clinical and biochemical remission, following at least 6 mo of combined immunosuppressive therapy, consideration can be made to withdrawing thiopurine therapy in the correct patient with close follow-up. |
| Publish Date |
2018-08-27 07:22 |
| Citation |
Reinglas J, Gonczi L, Kurt Z, Bessissow T, Lakatos PL. Positioning of old and new biologicals and small molecules in the treatment of inflammatory bowel diseases. World J Gastroenterol 2018; 24(32): 3567-3582 |
| URL |
http://www.wjgnet.com/1007-9327/full/v24/i32/3567.htm |
| DOI |
http://dx.doi.org/10.3748/wjg.v24.i32.3567 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345
